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We report the first outbreak of carbapenem-resistant 
NDM-1-producing Acinetobacter baumannii in Europe, 
in a French intensive-care unit in January to May 2013. 
The index patient was transferred from Algeria and 
led to the infection/colonisation of five additional 
patients. Concurrently, another imported case from 
Algeria was identified. The seven isolates were geneti-
cally indistinguishable, belonging to ST85. The blaNDM-1 
carbapenemase gene was part of the chromosom-
ally located composite transposon Tn125. This report 
underscores the growing concern about the spread of 
NDM-1-producing A. baumannii in Europe.
Background 
The emergence and spread of New-Delhi metallo-beta-
lactamase (NDM)-producing Gram negative isolates 
constitutes a new wave of multidrug-resistant (MDR) 
bacteria [1]. First identified from Enterobacteriaceae, 
the blaNDM gene has since been identified in non-fer-
menting bacterial species such as Pseudomonas aerug-
inosa and Acinetobacter baumannii [2,3]. Considering 
its ability to be the source of nosocomial outbreaks, 
carbapenem-resistant A. baumannii (AB) represents 
a threat for critically ill hospitalised patients [4]. We 
report here the first outbreak of NDM-1-producing AB 
in Europe, which occurred in a French surgical inten-
sive-care unit in January to May 2013.
Outbreak description
The index case (Patient 1) was a female patient in her 
early 80s suffering from end-stage cirrhosis. She origi-
nated from Algeria but lived mostly in France. During 
a stay in Algeria in December 2012, she was admit-
ted into a private hospital in the city of Tizi Ouzou 
following renal failure, which required dialysis. After 
one month in hospital, she was repatriated to France 
due to liver decompensation. On 18 January 2013, she 
was admitted to a 15-bed surgical intensive-care unit 
of a tertiary care university hospital in a Paris sub-
urb. In accordance with local and national policy, she 
was screened on admission for carriage of MDR bac-
teria. Rectal screening revealed MDR-A. baumannii 
(MDR-AB) (Isolate 1) that was susceptible only to ami-
kacin, netilmicin and colistin (Table). The same day, 
she was intubated for respiratory failure. Protected 
distal bronchial brushing yielded a culture of MDR-AB 
with the same antibiotic resistance profile. A combina-
tion of intravenous tigecycline and amikacin was given. 
On 24 January, she developed multivisceral failure and 
died four days later. During the following days, three 
additional patients with MDR-AB infection and/or colo-
nisation were identified in the same unit. A cirrhotic 
male patient in his mid-60s (Patient 2) – who had been 
hospitalised since 3 January 2013 and confirmed free 
of MDR bacteria on admission – developed a ventila-
tor-associated pneumonia on 26 January. Culture of a 
distal protected specimen yielded MDR-AB (Isolate 2). 
This patient was successfully treated by a combination 
of tigecycline and amikacin and was extubated two 
days later. Patient 3 was a male liver-transplant patient 
in his mid-60s who was not colonised on admission 
but developed a dialysis catheter-related bloodstream 
infection due to a MDR-AB on 28 January (Isolate 3). 
Imipenem and amikacin combination was prescribed 
but the patient died of haemorrhagic shock before 
antibacterial susceptibility results could be obtained. 
Patient 4 was a dual renal- and liver-transplant female 
patient in her late 40s from whom an abdominal drain 
yielded an MDR-AB culture on 2 February (Isolate 4). 
This patient recovered without receiving any antibiotic 
therapy and was discharged from the hospital on 11 
February. 
Two weeks after the admission of the index case, a 
woman in her early 80s (Patient 5) suffered from a cer-
ebrovascular accident and was repatriated from the 
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same Algerian county that Patient 1 was repatriated 
from (but from a different healthcare facility) to the 
emergency unit of our hospital. A screening test per-
formed on admission identified MDR-AB (Isolate 5).
Two months after this first cluster of five patients with 
MDR-AB, two additional patients free of MDR bacte-
ria on admission to the surgical intensive-care unit 
described acquired a MDR-AB during their stay in this 
unit. A woman in her late 50s (Patient 6) was admit-
ted to the surgical intensive-care unit on 6 April and 
placed in the room where the index case had stayed. 
This patient was found positive for MDR-AB on 15 April 
in specimens from a catheter and the respiratory tract 
(Isolate 6). She was treated with intravenous tigecy-
cline and aerosolised colistin. She underwent success-
ful liver transplantation on 22 April and recovered well. 
The last patient (Patient 7) was a man in his late 50s 
admitted to the surgical intensive-care unit on 3 April 
for a liver transplant and from whom a rectal swab 
yielded MDR-AB a month later (Isolate 7). The patients’ 
duration of hospital stay, time of infection and/or col-
onisation and location in the hospital are reported in 
Figure 1.
Laboratory analysis
Identification of the seven MDR-AB strains at the spe-
cies level was confirmed by 16S RNA sequencing (data 
not shown). Their antimicrobial susceptibilities were 
tested by minimum inhibitory concentration (MIC) 
determination (Etest, bioMérieux, France) (Table) and 
interpreted according to EUCAST guidelines [5]. All 
isolates exhibited a high level of resistance to penicil-
lins, broad-spectrum cephalosporins, carbapenems, 
fluoroquinolones and trimethoprim-sulfamethoxazole. 
Those isolates remained susceptible only to netilmicin, 
colistin and amikacin. The production of a class B car-
bapenemase was suspected by the positive results of 
the imipenem/imipenem plus EDTA test using MIC dou-
ble strips (Etest, bioMérieux, France) (Table 1) and con-
firmed by UV spectrophotometry [6]. Carbapenemase 
genes were screened by PCR as described and the 
blaNDM-1 gene was amplified in the seven isolates [7]. 
Genotypic comparison by pulsed-field gel electro-
phoresis using restriction enzyme SmaI revealed an 
indistinguishable profile (data not shown). Diversilab 
(bioMérieux, France) analysis and multilocus sequence 
typing (MLST) typing confirmed that these isolates were 
clonally related and belonged to the same sequence 
type, ST85 (Figure 2) [8]. The genetic environment of 
blaNDM-1 was investigated as previously described [8] 
and showed that it was located in the composite trans-
poson Tn125 made of two copies of insertion sequence 
(IS) ISAba125.
Discussion 
Carbapenem-resistant A. baumannii are a source of 
deep concern due to their multidrug resistance pat-
tern and the ability of this bacterial species to persist 
in the environment [4,9,10]. Intensive-care units are 
particularly susceptible to outbreaks associated with 
Table 
Antimicrobial susceptibility of carbapenem-resistant  
NDM-1-producing Acinetobacter baumannii isolates, 
France, January–May 2013 (n=7)
Antibiotic
Isolates
MIC [µg/mL] (S/I/Ra)b
1 2 3 4 5 6 7
Ampicillin-
sulbactam 16 24 16 24 24 32 192
Ticarcillin-
clavulanic acid >256 >256 >256 >256 >256 >256 >256
Piperacillin >256 >256 >256 >256 >256 >256 >256
Piperacillin-
tazobactam >256 >256 >256 >256 >256 >256 >256
Aztreonam >256 >256 >256 >256 >256 >256 192
Ceftazidime >256 >256 >256 >256 >256 >256 >256
Cefepime >256 >256 >256 >256 >256 >256 >256
Meropenem >32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
Imipenem >32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
Imipenem/
imipenem + 
EDTA  ratiob
96 96 64 128 96 64 128
Doripenem >32
(R)
>32
(R)
>32
(R
>32
(R)
>32
(R)
>32
(R)
>32
(R)
Ciprofloxacin >32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
Gentamicin 32
(R)
24
(R)
24
(R)
32
(R)
24
(R)
32
(R)
64
(R)
Amikacin 8
(S)
12
(I)
8
(S)
8
(S)
8
(S)
8
(S)
64
(R)
Tobramycin 24
(R)
32
(R)
24
(R)
24
(R)
24
(R)
32
(R)
64
(R)
Netilmicin 0.75
(S)
1.5
(S)
0.5
(S)
0.75
(S)
0.75
(S)
0.75
(S)
1
(S)
Tetracycline 4 2 2 2 2 2 2
Tigecycline 0.75 1 1 1 1 0.25 0.38
Colistin 0.125
(S)
0.19
(S)
0.38
(S)
0.25
(S)
0.38
(S)
0.25
(S)
0.38
(S)
Trimethoprim-
sulfamethoxazole
>32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
>32
(R)
Fosfomycin 256 384 384 192 256 256 192
Rifampicin 6 6 6 6 6 32 8
MIC: mimimum inhibitory concentration; NDM: New-Delhi 
metallo-beta-lactamase.
a  Susceptible/Intermediary Resistant/Resistant categories from 
the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) guidelines [5], if determined.
b  Except for the imipenem/imipenem + EDTA ratio. The ratio was 
considered significant if >4. 
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MDR-AB: it is sometimes difficult for them to adhere 
strictly to infection control measures when patients 
require a high and persistent care-load. Four years 
ago, the same hospital faced a hospital-wide outbreak 
of MDR-AB colonisations and infections due to the 
importation of an index case from Tahiti [11]. Despite 
this experience and the implementation in 2010 at the 
national and local level of strict measures on hospital 
admission to detect, screen and place under contact-
isolation precautions repatriated patients, another 
outbreak linked to the admission of a patient previ-
ously hospitalised abroad again occurred [12]. 
Since 2010, NDM-producing MDR-AB has been iden-
tified in various parts of the world, in particular in 
North Africa and the Middle East [8,13-17]. A series of 
imported cases have been identified recently in Europe, 
such as in the Czech Republic, Germany, Slovenia, 
Switzerland and Belgium [8,13,14,17]. In France, the 
emergence of an NDM-1-producing MDR-AB strain 
originating from North Africa was recently highlighted 
[15,17]. We describe here the first outbreak associ-
ated with the importation of this NDM-1-producing 
A. baumannii clone ST85 in Europe. This report under-
lines the need for dedicated measures for patients 
previously treated in a hospital located in a ‘high risk’ 
geographical area. Such measures (e.g. screening for 
colonisation/infection with MDR organisms and isola-
tion nursing) should be maintained until the screen-
ing for colonisation/infection (e.g. using rectal, throat 
and wound swabs) has shown that these patients are 
free of MDR organisms. Because of intermittent car-
riage or lack of sensitivity of the current culture-based 
screening methods, repeated specimen collection and 
Figure 1
Timeline of patients infected/colonised with carbapenem-resistant NDM-1-producing Acinetobacter baumannii hospitalised 
in a surgical intensive-care unit, Créteil, France, January–May 2013 (n=6)
Rectal swab
Patient 7 Bed 19
colonisation
Patient 6 Bed 30
infection
Patient 4 Bed 18
colonisation Catheter-associated bacteremia
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infection Bronchial protected specimen
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Negative cultures
Positive cultures Surgical intensive-care unit 
Other ward
Death
Bed 30
Jan             Feb             Mar       Apr     May
17  18  19 20 21  22 23 24  25 26 27 28 29 30 31   1    2    3    4    5   6    7    8   9    10  11         15  16 17  18       30  31        6    7   8    9    10  11  12  13 14  15  16  17  18 19 20 21         1    2    3   4    5    6    7   8    
Date (2013)
First A. baumannii isolation
Catheter, bronchial protected specimen
Abdominal fluid and drain culture
Discharged
NDM: New-Delhi metallo-beta-lactamase.
Figure 2
Results of Diversilab and multilocus sequence typing 
analysis of isolates from patients infected/colonised with 
carbapenem-resistant NDM-1-producing Acinetobacter 
baumannii hospitalised in a surgical intensive-care unit, 
Créteil, France, January–May 2013 (n=6)
NDM: New-Delhi metallo-beta-lactamase.
The isolates from the hospitalised patients were compared with 
a collection of characterised strains [8,17]. A similarity line 
(89.4%) shows the cut-off to separate different clones.
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molecular-based methods of detection may help to 
control such outbreaks. 
Taking in account the relationship between North 
African countries and many European countries, it is 
possible that the spread of NDM-1 carbapenemase may 
occur rapidly, mostly through A. baumannii rather than 
Enterobacteriacae, since A. baumannii may become 
much more difficult to eradicate.
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